By continuing to use the site you agree to our Privacy & Cookies policy

NICE changes dronedarone guidance

NICE has changed draft recommendations on the use of dronedarone (Multaq) for atrial fibrillation – a disturbanceof the heart’s rhythm.

The institute has revised its first view that the drug should not be used and is now recommending the drug as a second-line treatment in people with additional cardiovascular risk factors whose AF has not been controlled by first-line therapy, usually including beta-blockers.

 

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!

newsletterpromo